UPTIDE
Research Database · 67 entries

Research Database

Peer-referenced literature underlying the Uptide compound catalogue. Each card opens a curated study profile with summary, methodology, focus, limitations and the related compound.

67 of 67 entries
2026preclinical (rat coronary ligation)·GHRP-6·Endocrine Research

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.

Wang L, Rodriguez-Ulloa A, Berlanga-Acosta J, et al. · Pharmaceuticals (Basel)

Chronic GHRP-6 administration reduced post-infarct ventricular remodeling and improved systolic function in a permanent coronary ligation model, consistent with cytoprotective and anti-fibrotic effects mediated through growth hormone secretagogue receptor signalling.

PMID 41901314 PMC13029777 DOI Open study profile →
2025clinical trial (older adults)·NAD+·Metabolic Research

Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health in older adults.

Multiple authors. · Journal of Pharmacology and Experimental Therapeutics

Oral nicotinamide riboside supplementation in older adults was associated with measurable changes in markers of vascular function, supporting investigation of NAD+ precursors as a strategy for age-related endothelial decline.

PMID 40479886 PMC13095416 DOI Open study profile →
2021clinical trial (randomized, prediabetic postmenopausal women)·NAD+·Metabolic Research

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Yoshino M, Yoshino J, Kayser BD, et al. · Science

Ten weeks of oral nicotinamide mononucleotide (NMN) increased skeletal-muscle insulin sensitivity and altered insulin-signalling protein expression in prediabetic postmenopausal women, the first randomized clinical demonstration of a metabolic effect of NMN supplementation in humans.

PMID 33888596 PMC8550608 DOI Open study profile →
2019preclinical (rat ethanol model)·Selank·Neuroscience Research

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Kolik LG, Nadorova AV, Antipova TA. · Bulletin of Experimental Biology and Medicine

Selank attenuated ethanol-induced memory impairment and normalised hippocampal and prefrontal BDNF levels, supporting a neuroprotective mechanism linked to BDNF modulation.

PMID 31625062 DOI Open study profile →
2016review (clinical pharmacology)·Melanotan-II·Dermatological Research

Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

Lane AM, McKay JT, Bonkovsky HL. · The Application of Clinical Genetics

Reviews trial data showing that the α-MSH analogue afamelanotide (Scenesse) reduces phototoxic pain and increases pain-free sunlight exposure in patients with erythropoietic protoporphyria, providing the strongest regulated clinical evidence for therapeutic melanocortin receptor agonism.

PMID 28003770 PMC5161401 DOI Open study profile →
2011clinical practice guideline·HGH Somatropin·Endocrine Research

Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Molitch ME, Clemmons DR, Malozowski S, et al. · Journal of Clinical Endocrinology & Metabolism

Endocrine Society guideline establishing recommended diagnostic provocative testing, candidate patient selection, dosing principles and monitoring framework for recombinant human growth hormone replacement in adults with documented GH deficiency.

PMID 21602453 DOI Open study profile →
2010preclinical (rat cerebral ischemia)·Semax·Neuroscience Research

Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.

Dmitrieva VG, Povarova OV, Skvortsova VI, et al. · Cellular and Molecular Neurobiology

Semax and its C-terminal fragment Pro-Gly-Pro increased transcription of BDNF, NGF and their cognate receptor genes following cerebral ischemia, supporting a neurotrophin-mediated neuroprotective mechanism.

PMID 19633950 PMC11498467 DOI Open study profile →
2008clinical (randomized double-blind, men with erectile dysfunction)·Melanotan-II·Dermatological Research

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Safarinejad MR, Hosseini SY. · Journal of Urology

Subcutaneous bremelanotide (a melanocortin receptor agonist closely related to Melanotan-II) produced statistically significant improvements in erectile response in men who had failed sildenafil therapy.

PMID 18206919 DOI Open study profile →
2008clinical (GAD and neurasthenia patients)·Selank·Neuroscience Research

Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia.

Zozulia AA, Neznamov GG, Siuniakov TS, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

Open clinical investigation reported anxiolytic efficacy of intranasal Selank in patients with generalized anxiety disorder and neurasthenia, with a tolerability profile distinct from benzodiazepines.

PMID 18454096 Open study profile →
2005clinical (men with erectile dysfunction)·Melanotan-II·Dermatological Research

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

Diamond LE, Earle DC, Garcia WD, et al. · Urology

Low-dose intranasal PT-141 (bremelanotide) combined with sildenafil produced an enhanced erectile response versus either agent alone, demonstrating central melanocortin involvement in penile erection.

PMID 15833522 DOI Open study profile →

Study information is provided only to describe published research methodology and scientific context. It is not medical advice, dosing guidance, administration guidance, or a therapeutic recommendation.